ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0032

Increased Expression of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues During the Early Evolution of Collagen-Induced Arthritis

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0464

Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0043

Inflammatory and Angiogenic Serum Profile of Refractory Rheumatoid Arthritis

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0396

Inflammatory Markers of Autoimmune Uveitis in the Eye, Tears and Blood

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0049

Inflammatory Priming by Anti-MAA Antibodies in Rheumatoid Arthritis

RA – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0305

Inflammatory T Cell Expansion in Yao Syndrome

Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0681

Influence of Occupational Exposure to Pollutants on Clinical and Serological Phenotypes in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0078

Inhibition of the Deubiquitinase TRABID in a Pre-clinical Mouse Model of Axial Spondyloarthritis Decreases Disease Severity

SpA Including PsA – Basic Science Poster

10:30AM-12:30PM: Abstract Number: 0733

Inpatient Outcomes in ANCA-Associated Vasculitis: An In-Depth Cross-Sectional Analysis Using NIS Data (2016-2020)

Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0466

Inpatient Outcomes of Rheumatoid Arthritis in Hospitalized Patients Using Cannabis: Data from the National Inpatient Sample

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0734

Insights into Readmissions of ANCA-Vasculitis Patients: A Nationwide Analysis

Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0181

Integrated Multidisciplinary Lupus Social Work Program to Manage Social Determinants of Health in SLE and Lupus Nephritis – Preliminary Results

Healthcare Disparities in Rheumatology Poster I

10:30AM-12:30PM: Abstract Number: 0271

Intercritical Gout Represents a Systemic Inflammatory State

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0666

Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy

SLE – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0308

Interstitial Lung Disease as the First Clinical Manifestation of Connective Tissue Diseases

Miscellaneous Rheumatic & Inflammatory Diseases Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].